Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 1/2010

01.07.2010 | Gynecologic Oncology

GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin’s lymphoma patients

verfasst von: Markus Nitzschke, Juliane Raddatz, Michael K. Bohlmann, Petra Stute, Thomas Strowitzki, Michael von Wolff

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine the protective effect of gonadotropin-releasing hormone analogs (GnRHa) using several ultrasound and endocrine markers to detect ultrastructural ovarian damage in Hodgkin’s lymphoma patients.

Methods

Ten patients who had been treated for Hodgkin’s lymphoma and had received GnRHa to protect ovarian function were matched with patients at similar age, who had received the same chemotherapy regimens without GnRHa. In addition, ten healthy women at the same age were matched to the study groups to compare ovarian markers. Blood samples were drawn to determine anti-Müllerian hormone, Inhibin B, follicle-stimulating hormone and transvaginal ultrasound scans were performed to determine antral follicle count and ovarian volume. All women were asked about their menstrual cycle pattern.

Results

No difference was found when comparing the ovarian parameters of both study groups. Compared with healthy women, all ovarian parameters in the Hodgkin’s lymphoma patients were significantly different.

Conclusions

The results of this study demonstrate ultrastructural ovarian damage in Hodgkin’s lymphoma patients irrespective of GnRHa co-treatment. These findings do not support previous studies, showing GnRHa to protect ovarian function.
Literatur
1.
Zurück zum Zitat Meirow D, Nugent D (2001) The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 7:535–543CrossRefPubMed Meirow D, Nugent D (2001) The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 7:535–543CrossRefPubMed
2.
Zurück zum Zitat Sonmezer M, Oktay K (2004) Fertility preservation in female patients. Hum Reprod Update 10:251–266CrossRefPubMed Sonmezer M, Oktay K (2004) Fertility preservation in female patients. Hum Reprod Update 10:251–266CrossRefPubMed
3.
Zurück zum Zitat Blumenfeld Z, Avivi I, Ritter M, Rowe JM (1999) Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig 6:229–239CrossRefPubMed Blumenfeld Z, Avivi I, Ritter M, Rowe JM (1999) Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J Soc Gynecol Investig 6:229–239CrossRefPubMed
4.
Zurück zum Zitat Glode LM, Robinson J, Gould SF (1981) Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1:1132–1134CrossRefPubMed Glode LM, Robinson J, Gould SF (1981) Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet 1:1132–1134CrossRefPubMed
5.
Zurück zum Zitat Oktay K, Sönmezer M, Oktem O, Fox K, Emons G, Bang H (2007) Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 12:1055–1066CrossRefPubMed Oktay K, Sönmezer M, Oktem O, Fox K, Emons G, Bang H (2007) Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 12:1055–1066CrossRefPubMed
6.
Zurück zum Zitat Blumenfeld Z, von Wolff M (2008) GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 14:543–552CrossRefPubMed Blumenfeld Z, von Wolff M (2008) GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 14:543–552CrossRefPubMed
7.
Zurück zum Zitat Beck-Fruchter R, Weiss A, Shalev E (2008) GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update 14:541–542CrossRef Beck-Fruchter R, Weiss A, Shalev E (2008) GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update 14:541–542CrossRef
8.
Zurück zum Zitat Clowse ME, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, Bastian LA (2009) Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health 18:311–319CrossRef Clowse ME, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, Bastian LA (2009) Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health 18:311–319CrossRef
9.
Zurück zum Zitat Badawy A, Elnashar A, El-Ashry M, Shahat M (2009) Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91:694–697CrossRefPubMed Badawy A, Elnashar A, El-Ashry M, Shahat M (2009) Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril 91:694–697CrossRefPubMed
10.
Zurück zum Zitat Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA (2003) Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Müllerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 18:2368–2374CrossRefPubMed Bath LE, Wallace WH, Shaw MP, Fitzpatrick C, Anderson RA (2003) Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Müllerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 18:2368–2374CrossRefPubMed
11.
Zurück zum Zitat Larsen EC, Müller J, Rechnitzer C, Schmiegelow K, Andersen AN (2003) Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH < 10 IU/l. Hum Reprod 18:417–422CrossRefPubMed Larsen EC, Müller J, Rechnitzer C, Schmiegelow K, Andersen AN (2003) Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH < 10 IU/l. Hum Reprod 18:417–422CrossRefPubMed
12.
Zurück zum Zitat Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA (2006) The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21:2583–2592CrossRefPubMed Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA (2006) The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod 21:2583–2592CrossRefPubMed
13.
Zurück zum Zitat Avril C (2006) Antral follicle count and oocyte quality. J Gynecol Obstet Biol Reprod 35:2S42–2S43 Avril C (2006) Antral follicle count and oocyte quality. J Gynecol Obstet Biol Reprod 35:2S42–2S43
14.
Zurück zum Zitat Pavlik EJ, DePriest PD, Gallion HH, Ueland FR, Reedy MB, Kryscio RJ et al (2000) Ovarian volume related to age. Gynecol Oncol 77:410–412CrossRefPubMed Pavlik EJ, DePriest PD, Gallion HH, Ueland FR, Reedy MB, Kryscio RJ et al (2000) Ovarian volume related to age. Gynecol Oncol 77:410–412CrossRefPubMed
15.
Zurück zum Zitat Ataya K, Pydyn E, Ramahi-Ataya A, Orton CG (1995) Is radiation-induced ovarian failure in rhesus monkeys preventable by luteinizing hormone-releasing hormone agonists?: preliminary observations. J Clin Endocrinol Metab 80:790–795CrossRefPubMed Ataya K, Pydyn E, Ramahi-Ataya A, Orton CG (1995) Is radiation-induced ovarian failure in rhesus monkeys preventable by luteinizing hormone-releasing hormone agonists?: preliminary observations. J Clin Endocrinol Metab 80:790–795CrossRefPubMed
16.
Zurück zum Zitat Ataya K, Rao LV, Lawrence E, Kimmel R (1995) Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 52:365–372CrossRefPubMed Ataya K, Rao LV, Lawrence E, Kimmel R (1995) Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 52:365–372CrossRefPubMed
17.
Zurück zum Zitat Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W, Shalet S et al (1987) Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol 19:159–162CrossRefPubMed Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W, Shalet S et al (1987) Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol 19:159–162CrossRefPubMed
18.
Zurück zum Zitat Sverrisdottir A, Nystedt M, Johansson H, Fornander T (2009) Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 117:561–567CrossRefPubMed Sverrisdottir A, Nystedt M, Johansson H, Fornander T (2009) Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 117:561–567CrossRefPubMed
19.
Zurück zum Zitat Teinturier C, Hartmann O, Valteau-Couanet D, Benhamou E, Bougneres PF (1998) Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant 22:989–994CrossRefPubMed Teinturier C, Hartmann O, Valteau-Couanet D, Benhamou E, Bougneres PF (1998) Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant 22:989–994CrossRefPubMed
20.
Zurück zum Zitat Grigg AP, McLachlan R, Zaja J, Szer J (2000) Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). Bone Marrow Transplant 26:1089–1095CrossRefPubMed Grigg AP, McLachlan R, Zaja J, Szer J (2000) Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg). Bone Marrow Transplant 26:1089–1095CrossRefPubMed
21.
Zurück zum Zitat Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G (1985) Gonadal toxicity after combination chemotherapy for Hodgkin’s disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 21:601–605CrossRefPubMed Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G (1985) Gonadal toxicity after combination chemotherapy for Hodgkin’s disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 21:601–605CrossRefPubMed
22.
Zurück zum Zitat Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L (2007) Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 12:141–147CrossRefPubMed Giuseppe L, Attilio G, Edoardo DN, Loredana G, Cristina L, Vincenzo L (2007) Ovarian function after cancer treatment in young women affected by Hodgkin disease (HD). Hematology 12:141–147CrossRefPubMed
Metadaten
Titel
GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin’s lymphoma patients
verfasst von
Markus Nitzschke
Juliane Raddatz
Michael K. Bohlmann
Petra Stute
Thomas Strowitzki
Michael von Wolff
Publikationsdatum
01.07.2010
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 1/2010
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-009-1308-5

Weitere Artikel der Ausgabe 1/2010

Archives of Gynecology and Obstetrics 1/2010 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.